Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virpax Pharmaceuticals ( (VRPX) ) has provided an update.
On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.
More about Virpax Pharmaceuticals
YTD Price Performance: -87.16%
Average Trading Volume: 364,334
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.59M
Learn more about VRPX stock on TipRanks’ Stock Analysis page.